Want to see ONCY full AI Analyst Report?
ONCY Stock Chart & Stats
$0.81
-$0.01(-1.50%)
At close: 4:00 PM EDT
$0.81
-$0.01(-1.50%)
Day’s Range― - ―
52-Week Range$0.73 - $1.51
Previous CloseN/A
Volume317.18K
Average Volume (3M)1.42M
Market Cap
$106.34M
Enterprise Value$110.07
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Oct 30, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding127,510,506
10 Day Avg. Volume2,066,048
30 Day Avg. Volume1,415,275
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-22.05
Price to Sales (P/S)0.00
P/FCF Ratio-5.71
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside640.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Clinical Efficacy In Colorectal CancerREO 022 data showing a ~19.5-month median duration of response and a ~33% objective response rate in second-line KRAS-mutant MSS colorectal cancer indicate clinically meaningful, durable benefit versus historical benchmarks. Such robust efficacy in a hard-to-treat population can support registrational pathways, strengthen partner interest, and form a lasting clinical differentiation that underpins commercialization potential if confirmed in randomized trials.
Regulatory Momentum With FDA EngagementFast Track designation plus documented FDA alignment on pivotal trial design materially reduce regulatory uncertainty and can accelerate development and review timelines. This durable regulatory progress supports the feasibility of accelerated or full approval pathways, improving prospects for earlier market access and making long-term partnership or licensing discussions more actionable for a clinical-stage biotech.
Manufacturing Patent And Layered IP ProtectionIssuance of a manufacturing patent through 2044 and a layered patent strategy (with potential method-of-use protection to 2046) strengthens Oncolytics' commercialization preparedness. Durable IP around scalable production and use cases lowers risk of manufacturing bottlenecks, enhances bargaining power with partners, and helps create a longer-term competitive moat if pelareorep reaches the market.
Bears Say
Zero Revenue And Persistent Cash BurnThe company reports no product revenue while burning significant cash (TTM operating and free cash flow roughly -$20.9M and a TTM net loss near $31.3M). This persistent negative cash generation creates structural dependency on external financing or partnerships to fund pivotal trials and commercialization, increasing dilution and execution risk over the medium term if capital alternatives are constrained.
Deteriorated Balance Sheet And Negative EquityEquity turning negative and a material decline in total assets (to roughly $8.2M TTM) materially reduce the company's financial cushion despite low absolute debt. This weakened solvency profile limits flexibility to absorb trial delays or unexpected costs, likely forces more frequent or dilutive capital raises, and raises longer-term sustainability concerns for advancing registrational programs without strategic funding.
Nasdaq Minimum Bid Price Noncompliance RiskReceipt of a Nasdaq notice for sub-$1.00 trading creates a near-term delisting risk and structural marketability concern. Prolonged noncompliance can impair liquidity, make capital raises more difficult or costly, and deter potential partners or investors, all of which can materially constrain the company's ability to fund trials or execute long-term development plans over the next several months.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.73 and its highest was $1.51 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $106.34M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Oct 30, 2026 which is in 75 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Aug 12, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.055 by -$0.025.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.06.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 127,510,506 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.055. Following the earnings report the stock price went down -2.795%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (640.74% Upside)
$6.00 (640.74% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.89%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$6.00
▲(640.74% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―